Related Experiment Video
Updated: Aug 10, 2026
Establishment and Propagation of Human Retinoblastoma Tumors in Immune Deficient Mice
Published on: August 4, 2011
Responsiveness of retinoblastoma to local diaziquone. Studies in a xenograft model
1Children's Leukaemia and Cancer Research Unit, Prince of Wales Children's Hospital, Randwick NSW, Australia.
Abstract:
The benefits of chemotherapy in the management of early or bilateral retinoblastoma are doubtful and are difficult to study. A xenograft model has been developed in which the therapeutic response of retinoblastoma heterotransplanted to the anterior chambers of nude mouse eyes can be evaluated. Cyclophosphamide has been shown to be the most effective of the conventional agents. The new drug diaziquone was tested in the model against five patient-derived xenografted cell lines, using both systemic (intraperitoneal) and local (eye drops) methods of administration. A total of 359 xenograft tumors in 229 experimental animals were monitored after treatment with intraperitoneal cyclophosphamide, intraperitoneal diaziquone, or local diaziquone. Responses to all three regimens were demonstrated in each of the five xenograft lines. Diaziquone compared favorably with cyclophosphamide as systemically administered chemotherapy. Local diaziquone was as effective as intraperitoneal injection in producing tumor responses. It is suggested that methods for local administration of diaziquone may be adapted to the clinical setting, and that a role for this modality may be found in a combination of nonoperative approaches to the management of small, intraocular tumors.
Insights
Chemotherapy for retinoblastoma shows limited benefits. Local administration of diaziquone, a new drug, proved effective in a mouse model, suggesting potential for treating intraocular tumors.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Chemotherapy's efficacy in early or bilateral retinoblastoma is uncertain and challenging to research.
- A novel xenograft model allows for evaluating retinoblastoma treatment responses in vivo.
- Cyclophosphamide is recognized as a leading conventional chemotherapeutic agent.
Purpose of the Study:
- To assess the efficacy of diaziquone against retinoblastoma using a xenograft model.
- To compare systemic and local administration of diaziquone with systemic cyclophosphamide.
- To explore the potential of local diaziquone delivery for intraocular retinoblastoma management.
Main Methods:
- Development of a xenograft model using retinoblastoma heterotransplanted into nude mouse eyes.
- Testing diaziquone via intraperitoneal injection and eye drops against five patient-derived xenograft cell lines.
- Monitoring tumor response in 359 xenografts across 229 experimental animals.
Main Results:
- All tested regimens (intraperitoneal cyclophosphamide, intraperitoneal diaziquone, local diaziquone) showed responses in all five xenograft lines.
- Systemic diaziquone demonstrated comparable efficacy to systemic cyclophosphamide.
- Local administration of diaziquone achieved tumor responses equivalent to systemic administration.
Conclusions:
- Diaziquone is a promising agent for retinoblastoma treatment, performing well against cyclophosphamide.
- Local diaziquone delivery is as effective as systemic administration, offering a viable alternative.
- Local diaziquone administration may be adaptable for clinical use in managing small, intraocular retinoblastoma, potentially in combination therapies.
